OncoMatch/Clinical Trials/NCT07335497
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Official title: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Is NCT07335497 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments for locally advanced / metastatic solid tumors.
Treatment: CR-001 · Paclitaxel · trifluridine and tipiracil · Pemetrexed · Carboplatin · Oxaliplatin · Gemcitabin · Cisplatin · Capecitabine · FOLFOX — The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Cholangiocarcinoma
Endometrial Cancer
Cervical Cancer
Ovarian Cancer
Gastric Cancer
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1 therapy
Has received prior anti-PD-1/L1 treatment
Cannot have received: allogeneic stem cell transplant
Has undergone prior allogeneic stem cell or solid organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Study Site · Birmingham, Alabama
- Clinical Study Site · Los Angeles, California
- Clinical Study Site · Denver, Colorado
- Clinical Study Site · Washington D.C., District of Columbia
- Clinical Study Site · Orlando, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07335497 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1/PD-L1 therapy, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify